{"entity":{"id":"nct06842498","kind":"trial","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","aka":[],"tldr":"A phase 2 trial of FG-3246 in prostate cancer, run by Kyntra Bio, now recruiting.","summary":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT06842498 by Kyntra Bio, with 75 participants planned, started 2026-02-22 and due to reach its primary completion in 2028-03-31. Interventions recorded: FG-3246.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06842498","url":"https://clinicaltrials.gov/study/NCT06842498"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06842498","phase":"2","setting":"A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Kyntra Bio","started":"2026-02-22","startedType":"actual","enrolled":75,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06842498/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}